Join today and have your say! It’s FREE!

We will not release or resell your information to third parties without your permission.

Please Try Again

{{ error }}

By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Please Try Again

{{ error }}

Password Hint : {{passwordHint}}

Remember me

Forgot Password?

or

Privacy Policy | Disclaimer

Quote | Bullboard | News | Opinion | Profile | Peers | Filings | Financials | Options | Price History | Ratios | Ownership | Insiders | Valuation

Breaking & Recent News Theriva Biologics Inc TOVX

Healthcare Biotechnology

Theriva Biologics, Inc. is a diversified clinical-stage company developing therapeutics designed to treat cancer and related diseases in areas of high unmet need. It is advancing a new oncolytic adenovirus platform. Its candidates are VCN-01, SYN-004 (ribaxamase) and SYN-020. VCN-01 is an oncolytic adenovirus designed to replicate selectively and aggressively within tumor cells, and to degrade... see more

Add To Watchlist

Recent & Breaking News (NYSEAM:TOVX)

Synthetic Biologics to Report Second Quarter Results on August 10, 2015

PR Newswire July 29, 2015

The Biotech Rocket is Running Out of Fuel: Three Stocks to Keep You Soaring - Broad Street Alerts

Accesswire July 23, 2015

The Biotech Rocket is Running Out of Fuel: Three Stocks to Keep You Soaring - Broad Street Alerts

Accesswire July 23, 2015

Synthetic Biologics Announces Closing of Recent Equity Offering and Exercise in Full of Underwriters' Over-Allotment Option

PR Newswire July 21, 2015

Synthetic Biologics Announces Pricing of $40.0 Million Public Offering

PR Newswire July 16, 2015

Synthetic Biologics Announces Public Offering of Common Stock

PR Newswire July 15, 2015

Synthetic Biologics' Initiates SYN-010 Phase 2 Clinical Trial to Treat Irritable Bowel Syndrome with Constipation (IBS-C)

PR Newswire June 29, 2015

First Participant Dosed in Synthetic Biologics' Second Phase 2a Clinical Trial to Protect the Microbiome and Prevent C. difficile

PR Newswire June 12, 2015

Synthetic Biologics Presents Initial Data Validating Platform Expansion to Cover Carbapenem Antibiotics

PR Newswire June 3, 2015

Synthetic Biologics Expands Clinical & Regulatory Leadership Team with Addition of Klaus Gottlieb, MD, FACG

PR Newswire June 2, 2015

Synthetic Biologics to Host Microbiome Analyst & Investor Meeting

PR Newswire June 1, 2015

Synthetic Biologics' SYN-004 Microbiome-Protecting Preclinical Data Highlighted in Late-Breaking Poster at Digestive Disease Week® 2015

PR Newswire May 19, 2015

Synthetic Biologics' Novel SYN-010 Preclinical Data Featured in Digestive Disease Week® Poster

PR Newswire May 18, 2015

Synthetic Biologics Reports First Quarter 2015 Financial Results and Operational Highlights

PR Newswire May 11, 2015

Maureen Early Named Vice President, Commercial of Synthetic Biologics

PR Newswire May 7, 2015

Steven Shallcross Named Chief Financial Officer of Synthetic Biologics

PR Newswire May 4, 2015

Synthetic Biologics to Host First Quarter 2015 Investor Conference Call

PR Newswire April 30, 2015

Posters at ECCMID 2015 Highlight Preclinical Data from Synthetic Biologics' Novel SYN-005 Monoclonal Antibody Combination for the Treatment and Prophylaxis of Whooping Cough (Pertussis)

PR Newswire April 27, 2015

Synthetic Biologics' SYN-004 Clinical Data for Protection of Microbiome Selected for Poster Presentation at American Society of Microbiology 2015

PR Newswire April 1, 2015

Synthetic Biologics Initiates Phase 2a Clinical Trial of SYN-004 to Protect the Microbiome and Prevent C. difficile

PR Newswire March 30, 2015